SEC Form 4 · accession 0000899243-16-021002
REATA PHARMACEUTICALS INC · RETA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Colin John Meyer
Officer — See Remarks
Period of report
May 25, 2016
Accepted (ET)
May 26, 2016 · 12:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358762
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F2 | $11.00 | May 25, 2016 | A | 113,636 | A | — | May 25, 2026 | Class B common stock | 113,636 | 113,636 | D |
Explanation of responses
- F1The options vest in sixteen equal quarterly installments beginning on August 25, 2016, subject to continued service through each vesting date.
- F2The Class B common stock is convertible into Class A common stock on a one-for-one basis (a) at the holder's election at any time after the date that is six months following the date of the closing of the initial public offering of the company's Class A common stock, (b) at the holder's election prior to that time subject to certain conditions, or (c) at the option of the company's board of directors, in its sole discretion, at any time or multiple times from time to time on or before the closing of the initial public offering. The conversion right of the Class B common stock has no expiration date.
Remarks
Chief Medical Officer and Vice President, Product Development